Doppalapudi Rupa S, Riccio Edward S, Rausch Linda L, Shimon Julie A, Lee Pam S, Mortelmans Kristien E, Kapetanovic Izet M, Crowell James A, Mirsalis Jon C
SRI International, Biosciences Division, Menlo Park, CA 94025, USA.
Mutat Res. 2007 May 18;629(2):148-60. doi: 10.1016/j.mrgentox.2007.02.004. Epub 2007 Feb 25.
We conducted genetic toxicity evaluations of 11 candidate chemopreventive agents with the potential for inhibiting carcinogenesis in humans at increased risk of cancer. The compounds were evaluated for bacterial mutagenesis in the Salmonella-E. coli assay, for mammalian mutagenesis in mouse lymphoma cells, for chromosome aberrations in Chinese Hamster Ovary (CHO) cells, and for micronucleus induction in mouse bone marrow. Tested agents were indole 3-carbinol (I3C), bowman-birk inhibitor concentrate (BBIC), black tea polyphenols (BTP), farnesol, geraniol, l-Se-methylselenocysteine (SeMC), 5,6-dihydro-4H-cyclopenta[1,2]-dithiol-3-thione(DC-D3T), 4'-bromoflavone, 2,5,7,8-tetramethyl-(2R-[4R,8R,12-trimethyltridecyl] chroman-6-yloxy) acetic acid (alpha-TEA), SR13668 (2,10-dicarbethoxy-6-methoxy-5,7-dihydro-indolo[2,3-b] carbazole and SR16157 (3-O-sulfamoyloxy-7alpha-methyl-21-(2-N,N-diethylaminoethoxy)-19-norpregna-1,3,5(10)-triene). All these agents, except I3C and BTP, were negative in the Salmonella-E. coli assay in the presence and absence of metabolic activation (S9). I3C and BTP induced a weak mutagenic response in the presence and absence of S9 with strains TA100 and TA98, respectively. Of the three compounds tested in the mouse lymphoma assay (I3C, BBIC, and BTP), only BTP was mutagenic in the presence of S9. In the chromosomal aberration assay, of the 8 compounds that were tested, 4'-bromoflavone elicited a positive response in the absence of S9 only, while SR16157 was positive in the presence of S9. The results with geraniol remain inconclusive. I3C, BBIC and BTP were not tested in the chromosomal aberration assay. None of the 11 agents induced micronuclei in mouse bone marrow erythrocytes.
我们对11种候选化学预防剂进行了遗传毒性评估,这些药剂有可能抑制患癌风险增加的人类的致癌作用。对这些化合物进行了沙门氏菌-大肠杆菌试验中的细菌诱变评估、小鼠淋巴瘤细胞中的哺乳动物诱变评估、中国仓鼠卵巢(CHO)细胞中的染色体畸变评估以及小鼠骨髓中的微核诱导评估。受试药剂有吲哚-3-甲醇(I3C)、鲍曼-伯克抑制剂浓缩物(BBIC)、红茶多酚(BTP)、法尼醇、香叶醇、L-硒甲基硒代半胱氨酸(SeMC)、5,6-二氢-4H-环戊并[1,2]-二硫醇-3-硫酮(DC-D3T)、4'-溴黄酮、2,5,7,8-四甲基-(2R-[4R,8R,12-三甲基十三烷基]色满-6-基氧基)乙酸(α-TEA)、SR13668(2,10-二乙氧羰基-6-甲氧基-5,7-二氢-吲哚并[2,3-b]咔唑)和SR16157(3-O-氨磺酰氧基-7α-甲基-21-(2-N,N-二乙氨基乙氧基)-19-去甲孕甾-1,3,5(10)-三烯)。除I3C和BTP外,所有这些药剂在有无代谢活化剂(S9)存在的情况下,在沙门氏菌-大肠杆菌试验中均为阴性。I3C和BTP在有无S9存在的情况下,分别对TA100和TA98菌株诱导出微弱的诱变反应。在小鼠淋巴瘤试验中测试的三种化合物(I3C、BBIC和BTP)中,只有BTP在有S9存在的情况下具有诱变性。在染色体畸变试验中,受试的8种化合物中,4'-溴黄酮仅在无S9存在时引发阳性反应,而SR16157在有S9存在时呈阳性。香叶醇的结果尚无定论。I3C、BBIC和BTP未在染色体畸变试验中测试。11种药剂均未在小鼠骨髓红细胞中诱导微核形成。